Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Human EGFR Phosphorylation Array C1

Reactivity: Human AA Chemiluminescent Semi-Quantitative Cell Culture Supernatant, Cell Lysate, Plasma, Serum, Tissue Lysate Membrane
Catalog No. ABIN625608
  • Reactivity
    Human
    Detection Method
    Chemiluminescent
    Method Type
    Sandwich ELISA
    Application
    Antibody Array (AA)
    Purpose
    C-Series Human EGFR Phosphorylation Antibody Array 1 Kit. Detects 17 site specific and pan Human EGFRs. Suitable for all liquid sample types but intended for use with cell and tissue lysates.
    Brand
    RayBio®
    Sample Type
    Plasma, Cell Culture Supernatant, Serum, Cell Lysate, Tissue Lysate
    Analytical Method
    Semi-Quantitative
    Specificity
    EGFR (P-Tyr845), EGFR (P-Tyr992), EGFR (P-Tyr1045), EGFR (P-Tyr1068), EGFR (P-Tyr1086), EGFR (P-Tyr1148), EGFR (P-Tyr1173), EGFR (P-Ser1046/1047), EGFR (P-Ser1070), ErbB2 (P-Tyr877), ErbB2 (P-Tyr1112), ErbB2 (P-Tyr 1221/1222), ErbB2 (P-Tyr1248), ErbB2 (P-Thr686), ErbB2 (P-Ser1113), ErbB3 (P-Tyr1289), ErbB4 (P-Tyr1284)
    Characteristics
    • Easy to use
    • No specialized equipment needed
    • Compatible with nearly any liquid sample
    • Proven technology (many publications)
    • Highly sensitive (pg/mL)
    • Sandwich ELISA specificity
    • Higher density than ELISA, Western blot or bead-based multiplex
    Components
    Antibody Array Membranes
    Biotinylated Detection Antibody Cocktail
    Blocking Buffer
    Wash Buffers 1 and 2
    Cell & Tissue Lysis Buffer
    Detection Buffers C and D
    Plastic Incubation Tray
    Protease Inhibitor Cocktail (in select kits)
    Material not included
    Pipettors, pipet tips and other common lab consumables
    Orbital shaker or oscillating rocker
    Tissue Paper, blotting paper or chromatography paper
    Adhesive tape or Saran Wrap
    Distilled or de-ionized water
    A chemiluminescent blot documentation system (such as UVP's ChemiDoc-It® or EpiChem II Benchtop Darkroom), X-ray Film and a suitable film processor, or another chemiluminescent detection system.
  • Application Notes
    Perform ALL incubation and wash steps under gentle rotation or rocking motion (~0.5 to 1 cycle/sec) using an orbital shaker or oscillating rocker to ensure complete and even reagent/sample coverage. Rocking/rotating too vigorously may cause foaming or bubbles to appear on the membrane surface which, should be avoided. All washes and incubations should be performed in the Incubation Tray (ITEM 10) provided in the kit. Cover the Incubation Tray with the lid provided during all incubation steps to avoid evaporation and outside debris contamination. Ensure the membranes are completely covered with sufficient sample or reagent volume during each incubation. Avoid forceful pipetting directly onto the membrane, instead, gently pipette samples and reagents into a corner of each well. Aspirate samples and reagents completely after each step by suctioning off excess liquid with a pipette. Tilting the tray so the liquid moves to a corner and then pipetting is an effective method. Optional overnight incubations may be performed for the following step to increase overall spot signal intensities:
    - Sample Incubation
    - Biotinylated Antibody Cocktail Incubation
    - HRP-Streptavidin Incubation
    Comment

    The C-Series arrays feature chemiluminescent signal detection. The antibodies are spotted on nitrocellulose membrane solid supports and are handled in a very similar manner to Western blots.
    All C-Series arrays work on the sandwich ELISA principle, utilizing a matched pair of antibodies: an immobilized capture antibody and a corresponding biotinylated detection antibody.

    Sample Volume
    1 mL
    Plate
    Membrane
    Protocol
    1. Block membranes
    2. Incubate with Sample
    3. Incubate with Biotinylated Detection Antibody Cocktail
    4. Incubate with HRP-Conjugated Streptavidin
    5. Incubate with Detection Buffers
    6. Image with chemiluminescent imaging system
    7. Perform densitometry and analysis
    Reagent Preparation
    1. Protease Inhibitor Cocktail: Briefly spin down the Protease Inhibitor Cocktail tube before use. Add 60 µl of 1X Lysis Buffer into the vial to prepare a 100X Protease Inhibitor Cocktail Concentrate. 2. Phosphatase Inhibitor Cocktail Set II: Briefly spin down the Phosphatase Inhibitor Cocktail Set II tube before use. Add 180 µl of 1X Lysis Buffer into each vial to prepare 25X Phosphatase Inhibitor Cocktail Set II Concentrate. Dissolve the powder thoroughly by a gentle mix. 3. 2X Cell Lysis Buffer: Cell lysis buffer should be diluted 2-fold with deionized or distilled water before use. Add 20 µl of prepared 100X Protease Inhibitor Cocktail Concentrate and 20 µl of 100X Phosphatase Inhibitor Cocktail Set I Concentrate (bring Set I concentrate tube to room temperature to thaw the solution before use) , and 80 µl Phosphatase Inhibitor Cocktail Set II into 1.9 ml 1X Lysis Buffer before use. Mix well. 4. 20X Washing Buffer I or II: If the Wash Buffer Concentrate (20X) contains visible crystals, warm to room temperature and mix gently until dissolved. Dilute 25 ml of Wash Buffer Concentrate into deionized or distilled water to yield 500 ml of 1X Wash Buffer. 5. Cocktail of Biotin-Conjugated Anti-EGFR: Briefly spin the Detection Antibody tube before use. Add 100 µl of Blocking Buffer to the tube. Mix gently and transfer all mixture to a tube containing 2.1 ml of Blocking Buffer to prepare 1X Cocktail of Biotin-Conjugated Anti-EGFR. 6 . 1000X HRP-Conjugated Streptavidin: briefly spin down the HRP- Streptavidin Concentrate and pipette up and down to mix gently before use. E.g. add 5 µl of HRP-Conjugated Streptavidin concentrate into a tube with 5 ml Blocking Buffer. Mix gently to prepare 1X HRP-Conjugated Streptavidin (do not store the diluted Streptavidin for next day use). Note: mix tube containing 1,000X HRP-Conjugated Streptavidin well before use since precipitation may form during storage.
    Sample Preparation

    Use serum-free conditioned media if possible. If serum-containing conditioned media is required, it is highly recommended that complete medium be used as a control since many types of sera contains cytokines. We recommend the following parameters for your samples: 50 to 100 µl of original or diluted serum, plasma, cell culture media, or other body fluid, or 50-500 µg/ml of protein for cell and tissue lysates. If you experience high background or if the fluorescent signal intensities exceed the detection range, further dilution of your sample is recommended.

    Assay Procedure
    1. Place each membrane into the provided eight-well tray (- means the antibody printed side). 2. Add 2 ml 1X Blocking Buffer and incubate at room temperature for 30 min to block membranes. Note: incubation may be done at 4 °C for overnight. 3. Incubate membranes with 1ml of sample at room temperature for 1 to 2 hours. Dilute sample using 1X Blocking Buffer if necessary. Note: We recommend using 1 ml of Conditioned media or 1 ml of original or 10-fold diluted sera or plasma or 50-500 µg of protein for cell lysates and tissue lysates. Dilute the lysate at least 10 folds with 1 X blocking buffer. Note: The amount of sample used depends on the abundance of cytokines. More of the sample can be used if the signals are too weak. If the signals are too strong, the sample can be diluted further. Note: Incubation may be done at 4 °C for overnight. 4. Decant the samples from each container, and wash 3 times with 2 ml of 1X Wash Buffer I at room temperature with shaking. Please allow 5 min per wash. Dilute 20X Wash Buffer I with H 2 O. 5. Wash 2 times with 2 ml of 1X Wash Buffer II at room temperature with shaking. Allow 5 min per wash. Dilute 20X Wash Buffer II with H 2 O. 6. Prepare working solution for primary antibody. Add 100µl of 1X blocking buffer to the Biotin-Conjugated Anti- Cytokines tube. Mix gently and transfer all mixture to a tube containing 2 ml of 1X blocking buffer. Note: the diluted biotin-conjugated antibodies can be stored at 4 °C for 2-3 days. 7. Add 1 ml of diluted biotin-conjugated antibodies to each membrane. Incubate at room temperature for 1-2 hours. Note: incubation may be done at 4 °C for overnight. 8. Wash as directed in steps 4 and 5. 9. Add 2 ml of 1,000 fold diluted HRP-conjugated streptavidin (e.g. add 2 µl of HRP-conjugated streptavidin to 1998 µl 1X Blocking Buffer) to each membrane. Note: Mix the tube containing 1,000X HRP-Conjugated Streptavidin well before use since precipitation may form during storage. 10. Incubate at room temperature for 2 hours. Note: incubation may be done at 4 °C for overnight. 11. Wash as directed in steps 4 and 5.
      Do not let the membrane dry out during detection. The detection process must be completed within 40 minutes without stopping. 1. Proceed with the detection reaction. Add 250µl of 1X Detection Buffer C and 250µl of 1X Detection Buffer D for one membrane, mix both solutions. Drain off excess wash buffer by holding the membrane vertically with forceps. Place membrane protein side up ( - mark is on the protein side top left corner) on a clean plastic sheet (provided in the kit). Pipette the mixed Detection Buffer onto the membrane and incubate at room temperature for 2 minutes. Ensure that the detection mixture is completely and evenly covering the membrane without any air bubbles. 2. Drain off any excess detection reagent by holding the membrane vertically with forceps and touching the edge against a tissue. Gently place the membrane, protein side up, on a piece of plastic sheet ( - mark is on the protein side top left corner). Cover with another piece of plastic sheet on the array. Gently smooth out any air bubbles. Avoid using pressure on the membrane. 3. Expose the array to x-ray film (we recommend to use Kodak x-omat AR film) and detect signal using film developer. Or the signal can be detected directly from the membrane using a chemiluminescence imaging system. Expose the membranes for 40 seconds and then re-expose the film according to the intensity of signals. If the signals are too strong (background too high), reduce exposure time (e.g. 5-30 seconds). If the signals are too weak, increase exposure time (e.g. 5-20 min or overnight). Or re-incubate membranes overnight with 1x HRP-conjugated streptavidin, and redo detection in the second day. 4. Save membranes in -20° C to -80° C for future reference.
    Calculation of Results

    Visual comparison of array images may be sufficient to see differences in relative protein expression. However, most researchers will want to perform numerical comparisons of the signal intensities (or more precisely, signal densities), using 2-D densitometry. Gel/Blot documentation systems and other chemiluminescent or phosphorescent detection systems are usually sold as a package with compatible densitometry software. Any densitometry software should be sufficient to obtain spot signal densities from your scanned images. One such software program, ImageJ, is available for free from the NIH website along with an array plug-in.

    Assay Precision
    Inter-array Coefficient of Variation (CV) of spot signal intensities as low as 5% when run under optimal conditions.
    Restrictions
    For Research Use only
  • Handling Advice
    The antibody printed side of each membrane is marked by a dash (-) or number (#) in the upper left corner. Do not allow membranes to dry out during the experiment or they may become fragile and break OR high and/or uneven background may occur. Grasp membranes by the corners or edges only using forceps. DO NOT touch printed antibody spots.
    Storage
    -20 °C
    Storage Comment
    For best results, store the entire kit frozen at -20°C upon arrival. Stored frozen, the kit will be stable for at least 6 months which is the duration of the product warranty period. Once thawed, store array membranes and 1X Blocking Buffer at -20°C and all other reagents undiluted at 4°C for no more than 3 months.
    Expiry Date
    6 months
  • Kato, Iwama, Yamashita, Kobayashi, Fujihara, Fujimori, Kamada, Kobara, Masaki: "The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin." in: Oncology reports, Vol. 35, Issue 3, pp. 1582-92, (2016) (PubMed).

    Rios-Doria, Sabol, Chesebrough, Stewart, Xu, Tammali, Cheng, Du, Schifferli, Rothstein, Leow, Heidbrink-Thompson, Jin, Gao, Friedman, Wilkinson, Damschroder, Pierce, Hollingsworth, Tice, Michelotti: "A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways." in: Molecular cancer therapeutics, Vol. 14, Issue 7, pp. 1637-49, (2015) (PubMed).

    Arnold, Abdelmoez, Thurner, Debbage, Lukas, Skvortsov, Skvortsova: "Rac1 as a multifunctional therapeutic target to prevent and combat cancer metastasis." in: Oncoscience, Vol. 1, Issue 8, pp. 513-21, (2015) (PubMed).

    Montermini, Meehan, Garnier, Lee, Lee, Guha, Al-Nedawi, Rak: "Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content." in: The Journal of biological chemistry, Vol. 290, Issue 40, pp. 24534-46, (2015) (PubMed).

    Panupinthu, Yu, Zhang, Zhang, Gagea, Lu, Grandis, Dunn, Lee, Mills: "Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer." in: Oncogene, Vol. 33, Issue 22, pp. 2846-56, (2014) (PubMed).

    Siu, Ruzevick, Zhao, Connis, Jiao, Bettegowda, Xia, Burger, Hann, Gallia: "Erlotinib inhibits growth of a patient-derived chordoma xenograft." in: PLoS ONE, Vol. 8, Issue 11, pp. e78895, (2014) (PubMed).

    Slanina, Mündlein, Hebling, Schubert-Unkmeir: "Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells." in: Infection and immunity, Vol. 82, Issue 3, pp. 1243-55, (2014) (PubMed).

    Cheng, Wong, Alston, Mackenzie, Huang, Ouyang, Xie, Wiedmann, Rigas: "Aerosol administration of phospho-sulindac inhibits lung tumorigenesis." in: Molecular cancer therapeutics, Vol. 12, Issue 8, pp. 1417-28, (2013) (PubMed).

    Kesanakurti, Chetty, Rajasekhar Maddirela, Gujrati, Rao: "Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma." in: Cell death & disease, Vol. 3, pp. e445, (2013) (PubMed).

    Zhu, Belkhiri, El-Rifai: "DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib." in: Gastroenterology, Vol. 141, Issue 5, pp. 1738-48.e1-2, (2011) (PubMed).

    Godek, Sargiannidou, Patel, Hurd, Rothman, Tuszynski: "Angiocidin inhibits breast cancer proliferation through activation of epidermal growth factor receptor and nuclear factor kappa (NF-ĸB)." in: Experimental and molecular pathology, Vol. 90, Issue 3, pp. 244-51, (2011) (PubMed).

    Shalaby, Presneau, Ye, Halai, Berisha, Idowu, Leithner, Liegl, Briggs, Bacsi, Kindblom, Athanasou, Amary, Hogendoorn, Tirabosco, Flanagan: "The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target." in: The Journal of pathology, Vol. 223, Issue 3, pp. 336-46, (2010) (PubMed).

    Park, Tan, Datta, Lai, Zhang, Meng, Lim, Sze: "Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes." in: Molecular & cellular proteomics : MCP, Vol. 9, Issue 6, pp. 1085-99, (2010) (PubMed).

    Zhang, Ji, Yu, Overholtzer, Smolen, Wang, Brugge, Dyson, Haber: "YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway." in: Nature cell biology, Vol. 11, Issue 12, pp. 1444-50, (2009) (PubMed).

    Bhuvaneswari, Gan, Soo, Olivo: "Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response." in: Molecular cancer, Vol. 8, pp. 94, (2009) (PubMed).

  • Background
    The EGFR family of membrane receptors consists of four different proteins called EGFR/ErbB1/HER1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4. Under normal physiological conditions, the ErbB receptors play crucial roles in propagating signals regulating cell proliferation, differentiation, motility, and apoptosis. EGF receptor family shows clear differences between individual receptors, and also a large overlap. ErbB1 is the family member with most interaction partners and the highest percentage of tyrosine residues with more than one binding partner. ErbB3 is characterized by a large number of binding sites for phosphatidylinositol-3-kinase (PI3K), while ErbB2 has only few interaction partners with Shc as the most frequent one. ErbB1 and ErbB4 have a variety of phosphotyrosines that bind Grb2, or Grb2 and Shc. The ErbB1 and ErbB4 have a greater diversity of interaction partners than ErbB2 and ErbB3. ErbB1 and ErbB2 are often over-expressed or amplified in cancers, making them important targets for drugs currently in use or under development.
You are here:
Support